ATE401395T1 - Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren - Google Patents

Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren

Info

Publication number
ATE401395T1
ATE401395T1 AT02769340T AT02769340T ATE401395T1 AT E401395 T1 ATE401395 T1 AT E401395T1 AT 02769340 T AT02769340 T AT 02769340T AT 02769340 T AT02769340 T AT 02769340T AT E401395 T1 ATE401395 T1 AT E401395T1
Authority
AT
Austria
Prior art keywords
disorders
diseases
psychiatric
deacetylase inhibitors
treating neurodegenerative
Prior art date
Application number
AT02769340T
Other languages
English (en)
Inventor
Joan Steffan
Leslie Thompson
J Marsh
Laszlo Bodai
Judit Pallos
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE401395T1 publication Critical patent/ATE401395T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65—Genetically modified arthropods
    • A01K67/68—Genetically modified insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02769340T 2001-05-02 2002-05-02 Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren ATE401395T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28821501P 2001-05-02 2001-05-02
US37272402P 2002-04-11 2002-04-11

Publications (1)

Publication Number Publication Date
ATE401395T1 true ATE401395T1 (de) 2008-08-15

Family

ID=26964894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769340T ATE401395T1 (de) 2001-05-02 2002-05-02 Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren

Country Status (5)

Country Link
EP (1) EP1390491B1 (de)
AT (1) ATE401395T1 (de)
DE (1) DE60227658D1 (de)
ES (1) ES2310213T3 (de)
WO (1) WO2002090534A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2946810A1 (de) 2005-02-03 2015-11-25 TopoTarget UK Limited Kombinationstherapie mit einem HDAC-Hemmer und Vincristin zur Behandlung von Krebs
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0518235D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION
US7968604B2 (en) 2005-09-23 2011-06-28 Jeong-Woo Cho Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
EP2361619A1 (de) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone Deacetylase (hdac) Inhibitoren (pxd-101) zur Behandlung von hämatologischen Krebserkrankungen
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
JP2010514801A (ja) 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ, インコーポレイテッド ロミデプシンの精製
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
MX342913B (es) 2010-07-12 2016-10-19 Celgene Corp * Formas solidas de romidepsina y sus usos.
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2599479A1 (de) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure zur Behandlung der Alzheimer-Krankheit
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
PT2970139T (pt) 2013-03-15 2018-08-01 Biomarin Pharm Inc Inibidores de hdac
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN103861084A (zh) * 2014-02-12 2014-06-18 新乡医学院 Romidepsin在治疗帕金森病中的应用
WO2015142500A2 (en) 2014-03-21 2015-09-24 Bodybio Inc. Compositions and methods for treating addiction
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
EP3383494A4 (de) * 2015-12-04 2019-08-07 The Regents of The University of California Histondeacetylase-inhibitoren
AU2020353984B2 (en) 2019-09-27 2025-09-25 Takeda Pharmaceutical Company Limited 2-isoindol-1,3,4-oxadiazole derivatives useful as HDAC6 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Also Published As

Publication number Publication date
EP1390491B1 (de) 2008-07-16
WO2002090534A1 (en) 2002-11-14
EP1390491A1 (de) 2004-02-25
ES2310213T3 (es) 2009-01-01
EP1390491A4 (de) 2005-04-06
DE60227658D1 (de) 2008-08-28

Similar Documents

Publication Publication Date Title
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
TWI263503B (en) Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60325717D1 (de) Verfahren zur behandlung von angststörungen bei älteren personen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE323084T1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
DK1343472T3 (da) Thixotropisk næsespray
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE513471T1 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390491

Country of ref document: EP